Atopic Dermatitis
-
Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis
Johnson & Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723
Johnson & Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723
